Fellow Investor,
AXXE's trading session today was perfect as we saw it rise from it's drop yesterday and give traders today a beautiful gain to the tune of over 18 pct!
We'd like to congratulate all of you who took advantage of this bullish trade opportunity and capitalized today!
AXXE is STILL on our radar going forward as momentum is strong and it could potentially give traders even more gains ahead!
For those of you who missed AXXE's press release today and our initial report you can read it all here:
Axxess Pharma Reports VP of Business Development of ABG TapouT Reiterates AXXE Is Legal Licensee of TapouT Brand
Axxess Pharma, Inc. (OTCPINK: AXXE)
AXXE is a pharmaceutical company that engages in the marketing and distribution of various pharmaceutical products and diagnostic medical devices in Canada and internationally.
AXXE distributes dermatological, therapeutic nutritional, pain management, and diagnostic products.
AXXE’s principal product line includes Britical, Gravergol, Lactrase, Somnol, Triferexx, Urasal, Axspaz, Vivol, Hydraxx, Kemsol, Soropon, Amersol, Bactalase, Monurol, and Zynol, as well as skin care products.
AXXE distributes its products through physicians, hospitals, government and defense institutions, and pharmacies. The company was founded in 1997 and is headquartered in Markham, Canada.
Pain Management Gains Momentum – On Track to Reach $60 Billion
The highly fragmented pain-management market poses an opportunity for new classes of drugs targeting neuropathic pain as well as for generics as standard therapies come off patent. Because current therapies are often less than effective or have undesirable side effects, there also are emerging opportunities using genomics to match patients to pain medications.
Pain management today is dominated by Pfizer, Eli Lilly, Purdue Pharma, Endo Pharmaceuticals, Novartis, Johnson & Johnson, and Grünenthal. “Among these, Purdue Pharma, Endo, and Grünenthal specialize in pain,” points out Karen Holmes, senior market analyst and author of the recent Espicom Business Intelligence report, Evolution in the Pain Therapy Drugs Market: Nociceptive and Neuropathic Drug Development.
“Pfizer is by far the biggest player, consolidating its position with the acquisition of King Pharmaceuticals and Icagen. Including line extensions, Pfizer has at least 10 compounds in clinical development for pain indications.”
Whether those leaders will manage to maintain their positions depends upon how they manage their patent expirations as well as new drug development. “You have to be paranoid about the competition. The science isn’t stopping,” says John Steuart, managing partner, Claremont Creek Ventures. “Thousands of biotechs and tens of thousands of academic labs are working to develop new therapies all the time.” Pain management, he admits, is a mature market, so new therapies must be proven more efficacious or less toxic than existing medications.
Market Explosion
Market projections vary, but Espicom estimated the global pain-management market at $46.4 BLN at the close of 2011. The U.S. market accounts for 48% of that. Another market analyst, Global Industry Analysts (GIA), one year ago predicted the global pain-management market would reach $60 BLN by 2015.
That predicted growth is based upon an aging global population, increasing number of surgeries, lifestyle changes, and a rising incidence of cancer. Some 1.5 BLN of the world’s 7 BLN people—21%—currently suffer from pain. That includes approximately 30% of all cancer patients and 60% of late-stage cancer patients.
The largest markets for pain-management medications currently are the U.S. and Europe. As with many pharmaceuticals, however, the fastest-growing markets are expected to be in Asia and Latin America, according to the GIA analysis, Pain Management: A Global Strategic Business Report. It anticipates a 9% compounded annual growth rate for pain-management therapies in Latin America between 2007 and 2015.
Recent AXXE News Developments
Axxess Pharma to Launch High Protein, Fat Burning Ready to Drink (RTD) Protein Meal Replacement Products in Fall of 2014
TORONTO, ON--(Marketwired - Jun 24, 2014) - Axxess Pharma Inc. (PINKSHEETS: AXXE) a specialty pharmaceutical and nutritional supplements company is pleased to announce through its wholly-owned subsidiary, AllStar Health Brands Inc., that they will be launching a line high protein, fat burning Ready to Drink (RTD), protein meal replacement products in the fall of 2014. The early launch of these products was fueled by the strong feedback from several large, national US retailers.
Axxess has been working with its Australian distributor, and formulator, and has developed a suite of high demand, high-quality products. For years, the Australian and New Zealand dairy herds have been the optimal source for their whey protein and providing the finest protein supplements. These meal replacement/protein drinks have several advantages over the competition. Axxess Pharma believes this will translate into strong residual sales.
Dr. Bagi, President of Axxess Pharma stated: "The timing is perfect for these new products, especially with the high level of interest shown from our ECRM buyers' meetings of last week.
Thanks to the R & D efforts in Australia, we have developed a great tasting product with the added benefit of being able to integrate L-Carnitine into the formula, giving the products a unique combination of high protein intake, with the added benefit of fat-burning even when not working out."
Dr. Bagi, further stated, "This line of meal replacement protein-building products can satisfy both the high-performance athlete as well as persons just wishing to replace a meal with a product that will help them burn fat."
AXXE is ready for your attention right now and has huge momentum – roll with it.
Begin your due diligence today.
For information on AXXE please visit: http://www.axxesspharmainc.com/
Make sure you place AXXE on your screen tomorrow morning and stay tuned for further updates on this company.
Happy Trading
PsychoPennyStocks.com
Disclaimer
Never invest in any stock featured on our site or emails unless you can afford to lose your entire nvestment.
PSYCHOPENNYSTOCKS.com NEVER HAS & NEVER WILL ACCEPT FREE OR RESTRICTED \TRADING SHARES IN ANY COMPANIES MENTIONED AT PSYCHOPENNYSTOCKS.com &/OR ANY OF OUR SOCIAL NETWORKING PLATFORMS.
Full disclaimer can be read at: http://www.psychopennystocks.com/disclaimer.html
PLEASE NOTE WELL: The PsychoPennyStocks.com employees are not Registered as an Investment
Adviser in any jurisdiction whatsoever.
The disclaimer is to be read and fully understood before using our site, or joining our email list.
None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein.
Instead PsychoPennyStocks.com strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks.
PsychoPennyStocks.com does not offer such advice or analysis, and PsychoPennyStovcks.com further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries and extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be "forward looking statements". Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks an uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as "projects", "foresee", "expects", "will", "anticipates", "estimates", "believes", "understands", or that by statements indicating certain actions "may", "could", or "might" occur. Understand there is no guarantee past performance will be indicative of future results.
In preparing this publication, PsychoPennyStocks.com has relied upon information supplied by its customers, and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website.
Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however,
PsychoPennyStocks.com and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. PsychoPennyStocks.com has been compensated up to $15,000 for this profile of AXXE by a third party.
PsychoPennyStocks.com is not responsible for any claims made by the companies advertised herein. PsychoPennyStocks.com may receive compensation and its employees and affiliates may own stock that they have purchased in the open market either prior, during, or after the release of the companies profile which is an inherent conflict of interest in PsychoPennyStocks.com statements and opinions and such statements and opinions cannot be considered independent.
PsychoPennyStocks.com and its management may benefit from any increase in the share price of the profiled companies and hold the right to sell the shares bought at any given time including shortly after the release of the companies profile. Any and all compensation received in cash will always be disclosed below.
PsychoPennyStocks.com does not own any shares in any companies mentioned in this release. PsychoPennyStocks.com never accepts compensation in free-trading shares for it's marketing services of the company being profiled, however the third party that might have compensated PsychoPennyStocks.com may hold free-trading shares of the company being profiled and could very well be selling shares of the companies stock at the same time the profile is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration.
If PsychoPennyStocks.com ever accepts compensation in the form of free trading shares of the company being profiled and decides to sell these shares into the public market at any time before, during, or after the release of the companies profile our disclaimer will be updated accordingly reflecting the current position of those free trading shares received as compensation for our services.
